Therapy Using CAR-T Cells for Lung Cancer: Mechanism, Application and Further Development
DOI:
https://doi.org/10.54097/xrxqkj70Keywords:
Cancer, lung cancer, CAR-T therapy, immunotherapy.Abstract
Cancer, a formidable medical challenge, arises when body cells proliferate uncontrollably, deviating from their normal growth patterns. With over a hundred unique types, each variant of cancer is characterized by its specific causes, symptoms, and treatment modalities. Virtually no organ or tissue in the human body is immune to the potential onslaught of this disease. Among the myriad of treatments available, CAR-T cell therapy stands out as a revolutionary approach, especially in the realm of lung cancer treatment. This cutting-edge immunotherapy harnesses the body's own immune system to combat cancerous cells. This review delves deep into the intricacies of CAR-T cell therapy, elucidating its underlying mechanism and its specific role in targeting lung cancer. Furthermore, the article sheds light on the current applications of this therapy, its potential side effects, and its prospective advancements, offering hope for a future where lung cancer can be more effectively managed or even eradicated.
Downloads
References
Xu C, Ju D, Zhang X. Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer. Antibody Therapeutics, 2022, 5(1): 73–83.
Fischer J W, Bhattarai N. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Frontiers in Immunology, 2021, 12: 1–9.
Chen Y, Chang L, Yang, Y. CAR-T cell therapy in lung cancer. Journal of Hematology & Oncology, 2020, 13(1): 1-14.
[4] Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opinion on Biological Therapy, 2015, 15(8): 1145-1154.
Tang N, Cheng C, Zhang X, et al. B7-H3-CAR-T cells exhibited effective antitumor activity in ovarian cancer, neuroblastoma, and melanoma. Acta Pharmacologica Sinica, 2021, 42(5): 770-778.
Liu Y, Zhou N, Zhou L, et al. CAR-T cell therapy targeting PD-L1 for relapsed or refractory non-small cell lung cancer: an early phase I trial. Clinical Cancer Research, 2021, 27(1): 269.
Katz SI, Hammer SM, Levine JD, et al. Phase I Clinical Trial of Cellular Immunotherapy with Chimeric Antigen Receptor-Modified T Cells in Patients with Mesothelin-Expressing Cancers. Clin Cancer Res. 2021, 27(3): 812-821.
Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013, 1(1): 43-53.
Xiao B-F, Zhang J-T, Zhu Y-G, et al. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Frontiers in Immunology, 2021, 12: 1-16.
Li J, Li W, Huang K, et al. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. Journal of Hematology & Oncology, 2018, 11(1): 1–18.
Qu J, Mei Q, Chen L, et al. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunology, Immunotherapy, 2021, 70: 619–631.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
